Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.37 |
| ▸ | YAP1 | P46937 | 3/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.34 |
| ▸ | GCK | P35557 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL368710 | 0.93 | TLR9 (0.40) | TLR9TLR7PRMT5PDE4BPDE7A | |
| SCHEMBL15092140 | 0.91 | YAP1 (0.37) | TLR9TLR7PRMT5PDE4BPDE7A | |
| SCHEMBL369852 | 0.87 | TLR9 (0.41) | TLR9TLR7PDE4BPDE7AYAP1 | |
| SCHEMBL368745 | 0.87 | TLR9 (0.37) | TLR9TLR7PRMT5PDE4BPDE7A | |
| SCHEMBL367324 | 0.86 | PDE4B (0.38) | TLR9TLR7PRMT5PDE4BPDE7A | |
| SCHEMBL368809 | 0.86 | PDE4B (0.38) | TLR9TLR7PRMT5PDE4BPDE7A | |
| SCHEMBL369125 | 0.85 | PRMT5 (0.41) | TLR9TLR7PRMT5PDE4BPDE7A | |
| SCHEMBL15092068 | 0.85 | TLR9 (0.43) | TLR9TLR7PDE4BPDE7AGPR119 | |
| SCHEMBL369542 | 0.85 | MRGPRX4 (0.38) | TLR9TLR7PDE4BPDE7AGPR119 | |
| SCHEMBL369700 | 0.82 | TLR9 (0.43) | TLR9TLR7PRMT5YAP1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130178469-A1 | NOVEL ANTIVIRAL AGENTS | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (SIOC) (CN) | 2013-07-11 | — | — | US | disclosed |
| EP-2593460-A1 | 7, 9-NITROGEN RADICAL-4-OXO-4H-PYRIDO[L,2-A]PYRIMIDINE-2-CARBOXYLIC ACID BENZYLAMIDE ANTI-VIRALS | Avexa Limited (AU) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012006680-A1 | 7, 9-NITROGEN RADICAL-4-OXO-4H-PYRIDO[L,2-A]PYRIMIDINE-2-CARBOXYLIC ACID BENZYLAMIDE ANTI-VIRALS | AVEXA LIMITED (AU) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178469-A1 | NOVEL ANTIVIRAL AGENTS | EIF2AK2, IFNAR1, IRF3 | TLR9 177/4885TLR7 81/4885PRMT5 2769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.